Carolinas HealthCare System

Levine Cancer Institute
Study Leads to Practice-changing Implications for AML Patients
Dr. Ed Copelan Dr. Belinda Avalos

Edward Copelan, MD, and Belinda Avalos, MD, chair and vice-chair of the Hematologic Oncology and Blood Disorders program at Levine Cancer Institute, recently led a large international study with practice-changing implications for acute myeloid leukemia (AML) patients. The study was selected as the plenary article for publication in Blood, which is the nation’s leading hematology journal.

The study, from the Center for International Blood And Marrow Transplant Research, analyzed more than 1,200 patients who underwent transplantation from siblings or unrelated donors to compare the effectiveness of BuCy (a combination of the chemotherapy drugs cyclophosphamide and buslufan) and CyTBI (cyclophosphamide and total body irradiation) for the treatment of AML.The findings significantly favor the use of BuCy, due to improved transplant-related mortality and overall survival rates, as well as ease of administration.

Under Dr. Copelan and Dr. Avalos’ leadership, the Institute is dramatically expanding its hematology-oncology program including the development of a translational research lab devoted to testing new therapies and treatments for blood cancer patients and the construction of a new state-of-the-art hematologic malignancies unit, where bone marrow transplants will be performed.

Read the full study here.

About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.